Charles River Laboratories | CRL - Equity Capital And Reserves


Charles River Laboratories reported $2.84B in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
Agilent USD 7.12B 214M Mar/2026
Align Technology USD 4.23B 83.03M Jun/2026
Bio-Rad Laboratories USD 7.17B 322.6M Jun/2026
Bruker USD 2.44B 67M Jun/2026
Cardinal Health USD -2.88B 51M Jun/2026
Charles River Laboratories USD 2.84B 59.06M Jun/2026
Cigna USD 42.62B 410M Jun/2026
Concord Medical Services Hldg CNY -2.1B 136.32M Dec/2025
CVS Health USD 79.7B 2.25B Jun/2026
Danaher USD 52.58B 368M Jun/2026
Dentsply International USD 1.35B 33M Jun/2026
Elevance Health USD 44.88B 981M Jun/2026
Humana USD 19.21B 633M Jun/2026
Illumina USD 2.84B 162M Jun/2026
Incyte USD 6.34B 721.58M Jun/2026
Intrexon USD 43.17M 75.33M Jun/2024
IQVIA Holdings USD 6.17B 50M Jun/2026
Laboratory Of America USD 8.61B 121.8M Jun/2026
Lakefront Biotherapeutics EUR 3.26B 10.26M Jun/2026
Lonza CHF 9.13B 513M Dec/2025
McKesson USD -4.24B 2.07B Jun/2026
Merck EUR 30.17B 430M Jun/2026
Mettler Toledo International USD 12.82M 54.71M Jun/2026
Novartis USD 41.95B 3.02B Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Quest Diagnostics USD 7.52B 150M Jun/2026
Revvity USD 7.18B 67.62M Mar/2026
Thermo Fisher Scientific USD 51.93B 1.6B Mar/2026
United Therapeutics USD 6.4B 499.2M Jun/2026
UnitedHealth USD 105.32B 3.62B Mar/2026
Veradigm USD 1.02B 159.52M Dec/2022
Waters USD 15.29B 12.73B Mar/2026
West Pharmaceutical Services USD 2.99B 200K Jun/2026